mycoses

Diagnosis, Therapy and Prophylaxis of Fungal Diseases

Edited by/Herausgegeben von:

J. Müller (Editor-in-Chief), Emmendingen
H. C. Korting, München
Annemarie Polak-Wyss, Basel

Honorary Editor/Ehrenherausgegeber:

Yvonne M. Clayton, London

Editorial Board/ Herausgeberkollegium:

L. Ajello, Atlanta
G. S. de Hoog, Baarn
Carol A. Kauffman, Ann Arbor
H. Merk, Aachen
R. Rüchel, Göttingen

CABI BIOSCIENCE
EGHAM LIBRARY
11 SEP 2000

Volume 42 (1999)

REGISTER

Contents
Subject Index
Index of Authors

Blackwell Wissenschafts-Verlag Berlin · Vienna

Kurfürstendamm 57, D-10707 Berlin
Phone: (+49 30) 32 79 06-43 Fax: (+49 30) 32 79 06-10
E-mail: verlag@blackwis.de Internet Homepage: http://www.blackwell.de
Phone: (+431) 894 06 90-0 Fax: (+431) 894 06 90-24

Blackwell Science

CONTENTS

Issue 1/2

Editorial
The 42nd Volume

3–16 **R. Schwarze, A. Penk, L. Pittrow.**
(*Review*). Administration of fluconazole in children below 1 year of age
Fluconazol bei Kindern unter 1 Lebensjahr

17–19 **L. Pittrow, A. Penk.**
Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD)
Dosisanpassung von Fluconazol während kontinuierlicher Blutreinigungsverfahren (CAVH, CVVH, CAVHD, CVVHD)

21–28 **H. Tanuma.**
(*Review*). Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan
Pathogenese und Behandlung hyperkeratotischer Tinea pedis in Japan

29–32 **J. Morschhäuser, M. Ruhnke, S. Michel, J. Hacker.**
Identification of *CARE*-2-negative *Candida albicans* isolates as *Candida dubliniensis*
Identifizierung von *CARE*-2-negativen *Candida albicans*-Isolaten als *Candida dubliniensis*

33–36 **P. Roggentin, G. Krug, R. Schauer, J. Brasch.**
Lack of sialidase activity in *Candida albicans* and *Candida glabrata*
Candida albicans und *Candida glabrata* sind Sialidase-negativ

37–40 **H. Nikawa, H. Nishimura, T. Hamada, H. Yamashiro, L. P. Samaranayake.**
Effects of modified pellicles on *Candida* biofilm formations on acrylic surfaces
Der Einfluß modifizierter Haftflächen auf die *Candida*-Biofilmbildung an Acryloberflächen

41–46 **M. R. Elías-Costa, S. Carnovale, M. S. Relloso.**
Oropharyngeal candidosis in AIDS patients: an epidemiological study using restriction analysis of *Candida albicans* total genomic DNA
Epidemiologie der oralen Candidose bei AIDS-Patienten auf der Grundlage von Genom-DNA-Analysen

47–53 **T. Lorf, F. Braun, R. Rüchel, A. Müller, B. Sattler, B. Ringe.**
Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome®) after liver transplantation
Systemische Mykosen unter liposomaler Amphotericin B-Prophylaxe (Ambisome®) nach Lebertransplantation

55–60 **P. Nenoff, E. Taneva, B. Pfeil, U. Oswald, U.-F. Haustein.**
In vitro activity of rilopirox against fluconazole-susceptible and fluconazole-resistant *Candida* isolates from patients with HIV infection
In vitro-Aktivität von Rilopirox gegenüber Fluconazol-empfindlichen und Fluconazol-resistenten *Candida*-Isolaten von Patienten mit HIV-Infektion

61–65 **B. Willinger, M. Manafi.**
Evaluation of CHROMagar Candida for rapid screening of clinical specimens for *Candida* species
Bewertung von CHROMagar Candida zum Schnellnachweis von *Candida*-Arten aus klinischen Untersuchungsmaterial

67–70 **D. Harmsen, A. Schwinn, E.-B. Bröcker, M. Frosch.**
Molecular differentiation of dermatophyte fungi
Molekulare Differenzierung von Dermatophyten

71–74 **R. Kano, Y. Nakamura, T. Watari, S. Watanabe, H. Takahashi, H. Tsujimoto, A. Hasegawa.**
Species-specific primers of the chitin synthase 1 gene for the differentiation of the *Trichophyton mentagrophytes* complex
Artspezifische Primer des Chitinsynthase-1-Gens für die Differenzierung innerhalb des *Trichophyton mentagrophytes*-Komplexes

75–78 **G. S. Selvi, A. Kamalam, K. Ajithados, C. Janakai, A. S. Thambiah.**
Clinical and mycological features of dermatophytosis in renal transplant patients
Klinische Bilder und mykologische Befunde bei Dermatophytosen an Nierentransplantierten

79–91 **T. Matsumoto, H. Tanuma, S. Nishiyama.**
Clinical and pharmacokinetic investigations of oral itraconazole in the treatment of onychomycosis
Klinische und pharmakokinetische Untersuchungen zur oralen Itraconazol-Behandlung an Patienten mit Onychomykosen

93–96 **J. Chen, W. Liao, H. Wen, J. Wu, Z. Yao.**
A comparison among four regimens of itraconazole treatment in onychomycosis
Vergleichende Prüfung von vier Itraconazol-Behandlungsregimen bei Onychomykose

97–101 **M. K. Rai, S. Qureshi, A. K. Pandey.**
In vitro susceptibility of opportunistic *Fusarium* spp. to essential oils
In vitro-Empfindlichkeit opportunistischer *Fusarium*-Arten für ätherische Öle

103–106 **F. Staib.**
The green colour effect (GCE) of the killer strain *Cryptococcus laurentii* CBS 139 on Staib agar
Grünfarbeffekt des Killerstammes *Cryptococcus laurentii* CBS 139 auf Staib Agar

107–110 **Th. Vissiennon, K.-F. Schüppel, E. Ullrich, A. F. A. Kuijpers.**
(*Case report*). A disseminated infection due to *Chrysosporium queenslandicum* in a garter snake (*Thamnophis*)
Eine disseminierte *Chrysosporium queenslandicum*-Infektion bei einer Strumpfbandnatter (*Thamnophis*)

111–115 **C. Romano, R. Bilenchi, C. Alessandrini, C. Miracco.**
(*Case report*). Cutaneous phaeohyphomycosis caused by *Cladosporium oxysporum*
Kutane Phaeohyphomykose verursacht durch *Cladosporium oxysporum*

117–120 **G. K. Rieg, G. Just-Nübling, P. M. Shah, E. B. Helm, W. Stille.**
(*Case report*). Successful therapy of disseminated histoplasmosis in AIDS with liposomal amphotericin B
Fallbericht: Erfolgreiche Therapie disseminierter Histoplasmose bei AIDS mit liposomalem Amphotericin B

Issue 3

5th ECMM Congress in Dresden, 1999. Summaries
Meeting Report
H. Bernhardt.
Congress meeting
C. Abad-Zapatero, K. Stewart.
The role of protein crystallography and molecular modeling in targeted antifungal drug design
J. Beck-Mannagetta, B. Willinger.
Development of extramucosal aspergillosis of the maxillary sinus: the effect of extruded zinc oxide from endodontic therapy
H. Bernhardt.
German work on standardization
H. Bernhardt.
The continuous flow culture as a model in experimental mycology
M. Boogaerts.
Prophylactic and empiric antifungal strategies
M. Borg-von Zepelin, I. Meyer, D. Sanglard, M. Monod.
Inhibition of secreted aspartic *Candida* proteinases and reduction of adherence of *Candida* strains by different HIV proteinase inhibitors
J. Brasch.
Reliable distinguishing features of *Trichophyton mentagrophytes* var. *nodulare* remain to be defined
R. A. Calderone, J. A. Calera.
Signal proteins and the pathogenesis of candidiasis caused by *Candida albicans*

J.-M. Costa, D. Vidaud, M. Olivi, E. Bart-Delabesse, M. Vidaud, S. Bretagne.
TaqMan automated detection for circulating *Aspergillus fumigatus* DNA: implications for diagnosis on blood
D. W. Denning.
Non-*Aspergillus fumigatus* infection
E. Drouhet, M. Huerre.
Yeast tissue phase of *Emmonsia pasteuriana* inoculating in golden hamster by intratesticular way
B. Dupont.
Changing prevalence in systemic fungal infections
G. Ehninger, U. Schuler.
Fungal infections in immunocompromised patients in haematology/oncology: are new drugs affecting strategies of prophylaxis and treatment?
E. G. V. Evans. International perspective of standardization
E. Frangouli, A. Velegraki, A. Athanassopoulou, P. Paparhizos, P. Stromboulis, N. J. Legakis.
Oral candidiasis in HIV-infected individuals in Greece: incidence of *Candida* spp., *Candida albicans* serotypes and their susceptibility to antifungal agents
J. Gavalda.
Perspectives on aspergillosis therapy
M. A. Ghannoum, M. Bradley, N. Isham, S. Leidich, B. Elweski.
Genetic relatedness and antifungal susceptibilities of serial *Trichophyton rubrum* isolates from patients with onychomycosis of the toenail
F. A. Guhad, H. E. Jensen, J. Hau.
Development and validation of a new localized candidosis model: the Murine Mycotic Mastitis Model
J. Hacker, J. Morschhäuser.
Standardized molecular typing
D. Harmsen, J. Rothgänger, Y. Gräser, A. F. A. Kuijpers, J. Albert, M. Frosch, G. S. de Hoog.
Molecular diagnostics of fungi: ribosomal differentiation of medical microorganisms
R. J. Hay.
Topical versus systemic treatment for onychomycosis
H. Hebart, J. Löffler, C. Meisner, F. Serey, D. Schmidt, U. Schumacher, A. Böhme, H. Martin, A. Engel, D. Bunjes, W. Kern, L. Kanz, H. Einsele.
PCR for early diagnosis of aspergillosis following allo stem cell transplantation.
C. Hermann, J. Hermann, R. Hilgers, R. Rüchel.
Bacterial flora accompanying *Candida* yeasts in clinical specimens
B. Hube, M. Schaller, M. Bossenz, A. Mazur, D. Heß, A. Felk, S. Malz, W. Schäfer.
Molecular approaches to study virulence attributes in *Candida albicans*
G. Just-Nübling.
Management in AIDS patients with *Cryptococcus*
R. Kappe.
Mycological aspects of *in vitro* activity of voriconazole
R. Kappe, D. Rimek, C. Ilkenhans, M. Hartmann.
Disseminated *Penicillum marneffei* infection in an HIV patient from Thailand
C. C. Kibbler.
Antifungal prophylaxis with itraconazole oral solution
H. C. Korting.
Oral and cutaneous candidosis model based on reconstructed human epidermis
Marianne Kretschmar.
Murine model of *Candida* peritonitis
O. Kurzai, M. Frosch, D. Harmsen, W. Bautsch, F. A. Mühlschlegel.
Identification of *Candida dubliniensis* in oropharyngeal samples using a novel PCR test
K. K. Kwon-Chung, Y. C. Chang.
Cryptococcus and Cryptococcosis
J. Mayer, C. Bauer, S. Lempert, E.-B. Bröcker.
Onychomycosis and Tinea pedum caused by *Trichophyton tonsurans*

P. Mayser, G. Wille, W. Thoma, M. Winkeler, T. Monsees.
Nitrogen metabolism of *Malassezia* spp. and detection of new bisindoles: implications for the microecology, pathogenicity and differentiation of the genus
J. Meletiadis, J. Meis, A. Rijs, J. Mouton, J. Rodriguez-Tudela, P. Verweij.
In vitro susceptibility of 64 clinical *Scedosporium prolificans* and *S. apiospermum* isolates of antifungal agents
A. Menacci, E. Cenci, G. Del Sero, C. Fé d'Ostiani, C. Montagnoli, A. Bacci, L. Romani.
Immunoregulation in *Candida albicans* infection
H. Mensing, M. Bräutigam.
The tolerability and efficacy of lamisil in the light of the German Postmarketing Surveillance
F.-M. Müller.
Antimicrobial peptides as potential new antifungals
J. W. Murphy.
Immunological down-regulation of host defence in fungal infections
B. E. De Pauw.
Systemic mycotic infections: management in cancer patients
B. E. De Pauw.
Ten years of treatment of candidemia and invasive candidiasis
B. E. De Pauw.
Clinical experiences with the new antimycotic UK109, 496 (Voriconazole) in clinical trials
A. Pérez.
Terbinafine: broad new spectrum of indications in several subcutaneous and systemic mycoses and parasitic diseases
A. Polak.
The past and the future of combination therapy
H. G. Prentice.
Drug carrier systems for systemic antimycotics
D. Reimann, M.-L. Kerkmann, B. Nonnast-Daniel, P. Groß.
Serious subcutaneous infection by *Scedosporium apiospermum* in a kidney transplant patient, successfully managed by surgery and antimycotic therapy
D. Reinel.
Modern antifungal drugs in the treatment of onychomycosis
D. Reinel, E. Evans, B. Sigurgeirsson, S. Billstein, M. Bräutigam.
Terbinafine vs. intermittent itraconazole therapy in toenail mycosis: new results from the LION study
P. Reinl, P. Nenoff, U.-C. Hipler, U.-F. Haustein.
Malassezia furfur: In vitro susceptibility against antifungal agents and production of reactive oxygen species
J. Rodriguez-Tudela.
Scedosporium prolificans infections
V. Rickerts, A. Böhme, G. Just-Nübling.
Cluster of infections due to *Cunninghamella bertholletiae* in immunocompromised patients
E. Roilides, I. Kadiltsoglou, S. Tsaparidou, E. Bibashi, A. Gehrt, D. Nadal, H. Katsifa, G. Tudor-Williams.
Susceptibility of *Candida* spp. to human neutrophils: correlation with species but not with invasiveness or fluconazole sensitivity
M. Ruhnke, J. Roth, E. Engelmann, M. Mielke, C. A. Schmidt.
Comparative evaluation of PCR and serology for diagnosis of aspergillosis in patients with hematologic malignancies
N. S. Ryder.
Activity of terbinafine against serious fungal pathogens
M. Schaller, H. C. Korting, A. Felk, D. Hess, W. Schäfer, B. Hube.
Attenuated virulence of different *SAP* (secretory aspartyl proteinase) null mutants in an *in vitro* model of human oral candidosis

C. Scherwitz, A. Schach, H. Hügel, G. Schaumberg-Lever, B. Walker, S. Schmidt, K. Tintelnot, W. Stern, E. Knauss-Scherwitz, D. Zuder.
Imported coccidioidomycosis: four years after onset of the disease
A. F. Schmalreck, W. Fegeler.
Preliminary internal quality control ranges for antifungal agents tested by microdilution according to DIN 58940 against yeasts
E. Segal.
Experimental candidiasis: pathogenesis, prevention, therapy
G. Silling, W. Fegeler, N. Roos, M. Essink, T. Büchner.
Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B + 5-fluorocytosine
P. Staib, T. Nichterlein, G. Köhler, J. Morschhäuser.
Host-induced virulence gene expression in *C. albicans* during infection
C. Timpel, J. F. Ernst.
Role of surface glycosylation on morphogenesis and virulence of *Candida albicans*
K. Tintelnot, S. Adler, R. Baumgarten, A. Rosin, U. Kaben, H. Losert, M. Seibold.
Disseminated cryptococcoses without cryptococcal antigen detection
P. F. Troke.
New antifungals
M. L. Uffredi, G. Kac, G. Mangiapan, F. Lancastre.
Contribution of broncho-pulmonary specimens and immunological tests for the diagnosis of pulmonary aspergillosis due to *Aspergillus fumigatus* in patients hospitalized in a pneumology ward
I. Vennewald, M. Henker, E. Klemm, C. Seebacher.
Fungal infections of the paranasal sinuses
P. E. Verweij.
Infections by uncommon moulds: invasive zygomycosis
A. Warris, P. E. Verweij, R. Barton, J. Meis.
Invasive aspergillosis in two patients with Pearson syndrome
E. C. M. Williamson, J. P. Leeming.
Molecular approaches to *Aspergillus*
D. Badehorn, K. Becker, P. Ellinghaus, G. Peters, W. Fegeler.
Improved resolution of arbitrarily primed PCR patterns for yeast typing by prolonged ramping times
K. Becker, P. Schmalreck, D. Badehorn, I. Török, G. Peters, W. Fegeler.
Typing of *Candida (Torulopsis) glabrata* by arbitrarily primed polymerase chain reacion (AP-PCR) and Fourier transform-infrared spectroscopy
I. Berdicevsky, S. Saar.
Promising broad spectrum antifungal activity of a plant extract and its mode of action
H. Bernhardt, E. Segal, K. Zimmermann, K. Schulz, Z. Roth-Ben Arie, Z. Altboum, M. Knoke.
Morphologic variation of *C. albicans* mutants in continous flow culture
J. Bernhardt, K. Zimmerman, F. Feyerherd, M. Knoke, K. Schulz, H. Bernhardt.
Correlation of mycoserological results of candidosis of the orointestinal tract in intensive care patients
E. Bibashi, D. Sofianou, E. Kokolina, C. Kati, P. Kiriklidou, M. Papadimitriou.
Fungal peritonitis during continuous ambulatory peritoneal dialysis: a report of 32 cases
J. E. Birnbaum, M. A. Charif, K. D. Cooper, B. E. Elewski, M. A. Ghannoum.
Effect of terbinafine on restoration of immunologic reactivity to *Trichophyton* antigen
A. Budak, T. Zyss, B. Bogusz, A. Glowacka.
The planimetric and enymatic studies on the effect of magnetic stimulation on *in vitro* dermatophytes growth
A. Budak, T. Zyss, B. Bogusz, A. Glowacka.
The methodology of planimetric studies on the growth of dermatophyte colonies
D. Burhanoğlu, R. İnci, B. Karcı, A. Veral, A. Kokuludağp, S. Hilmioğlu, E. Tümbay.
Clinical forms and causative agents of fungal sinusitis

J. Chander, A. J. Kanwar, P. Lal, R. Sharma, M. S. Sekhon.
Recurrent actinomycetoma of amputated stump of the lower limb caused by *Actinomadura madurae*

B. Dworecka-Kaszak, F. N. Toka, A. Degórski, J. Sternicka.
Immunomodulation *in vivo* and *in vitro by Malassezia pachydermatitis* cell wall

I. Effendy, K. Strassman.
Longitudinal studies on survivability and antifungal susceptibility of dermatophytes causing toenail mycosis

A. El Barkani, M. Frosch, H. U. Mösch, F. Mühlschlegel.
LacZ as a reporter of gene expression in *Candida glabrata*

A. El-Naggar, Y. Ahmed, F. Ibrahim, M. Refai.
Mycotic abortion in small ruminants induced by *Candida albicans*

Ş. Ermertcan, R. İnci, S. Hilmioğlu, E. Tümbay.
The composition of macrodilution and colorimetric microdilution methods in determining the *in vivo* fluconazole susceptibility of *Candida* strains

W. Fegeler, J. Bille, B. Dupont, L. B. Edebo, D. H. Ellis, R. Kappe, A. Makristathis, J. F. G. M. Meis, H. Mittermayer, M. Ritzler, G. Schär, A.-F. Schmalreck, M. A. Viviani, B. Willinger.
Distribution of yeast species in clinical routine diagnostic specimen and their susceptibility against fluconazole, voriconazole and flucytosine

G. Fekete, G. Simon, I. Török.
Unusual appearance of mycotic infections on two renal transplant patients

K. Fischer, A. Wohlfarth, T. Denzel.
Persistent *Candida krusei* septicemia and cerebral zygomycosis in a leukaemic patient

S. Fuchs, U.-Ch. Hipler, A. Wilmer, U. Wollina.
Evaluation of four systems for identification of medically important yeasts

C. Fünfstück, U.-Ch. Hipler, B. Knöll, U. Wollina.
Cytotoxic effects of soluble *Candida albicans* factors on epithelial cells

A. Glöckner, M. Wiersbitzky, K. Schulz, H. Bernhardt.
Risk factors for systemic fungal infection in patients of a non-surgical ICU

T. Golubeva, P. Araviyskiy, M. Mikhaylova, I. Vybomova.
A model of mixed candidal-bacterial infection

B. Günther, M. Frosch, F. Mühlschlegel.
Defining potential targets for antimycotic therapy

A. Haas, G. Anding, C.-H. Grimm, K.-S. Boos.
Determination of itraconazole and its metabolite hydroxy-itraconazole by direct injection of human plasma into a coupled column liquid chromatographic system with on-line solid-phase extraction

L. Hagmeyer, J. Löffler, H. Hebart, H. Einsele.
Molecular and epidemiological analysis of azole-resistant *Candida* strains

K. Halmy.
Results of internal treatment of onychomycosis

P. Hamal, V. Raclavský, O. Hrušková, I. Píchová, I. Zelenková, J. Pavlíèek, P. Hejnar.
Characterization of nosocomial *Candida* strains: resistance to antifungal agents, proteinase production, RAPD typing

J. Hanzen, P. Hamal, A. Volleková, F. Horn, V. Raclavský, J. Pavlíček, O. Balogová.
Infection of liquor caused by *Candida lusitaniae*

A. Hetze, I. Vennewald, E. Wunderlich, H. Foelske, C. Seebacher.
Aspergillus endocarditis in a patient with ulcerative colitis and diabetes mellitus

U.-C. Hipler, C. Schröter, U. Wollina.
Fluorescence analysis of reactive oxygen species generated by *Candida albicans*: a comparison of yeast and hyphal forms

U.-C. Hipler, U. Wollina, D. Denning.
Fluorescence analysis of reactive oxygen species generated by six isolates of *Aspergillus fumigatus*

J. E. Hoppe, P. Frey.
Evaluation of six commercial tests and the germ tube test for presumptive identification of *Candida albicans*
C. J. Jackson, R. C. Barton, E. G. V. Evans.
Use of the ribosomal RNA genes (rDNA) to differentiate between dermatophytes and between strains of *Trichophyton rubrum*
J. Jeske, D. Dworniak, A. Głowacka, A. Ochęcka-Szymańska.
Histological and clinical picture of alimentary tract candidiasis
J. Jeske, A. Głowacka, A. Ochęcka-Szymańska.
Fungal infections in persons returning from the tropics
M.-L. Kerkmann.
Indoor climate effects in dwellings after installation of insulating windows and central heating systems and their influence on indoor mould infestation
O. K. Khmelnitsky, M. A. Sheviakov.
Immunological characteristic of *Candida*-commensalism and candidosis of colon mucosa
N. Klimko, M. A. Sheviakov, A. K. Mirzabalaeva.
Frequency of digestive tract *Candidosis* in women
M. Knoke, H. Bernhardt, K. Schulz, G. Schröder.
Fungaria in patients with systemic candidosis
V. G. Kornisheva, S. M. Ignatiyeva.
Role of *Candida* spp. in mycosis of hands and feet
J. Kunert.
Effect of peroxynitrite on dormant spores and germlings of *Aspergillus fumigatus in vitro*
A. Kurnatowska, E. Rakus-Andersson.
The application of a fuzzy set theory to diagnostical analysis of vaginal mycoses
M. Kurnatowski, K. Wasowska-Królikowska, A. Kurnatowska.
Biotypes of fungi isolated from children with alimentary tract diseases
P. Kurnatowski, A. Filipiak.
Otomycosis: the relationship between signs/symptoms and the species of the fungus
P. Kurnatowski, A. Grabek.
The influence of ketokonazole on the activity of some enzymes produced by *Candida* strains
P.-E. Lagneau, M. Bierny, M. Vercouter.
Incidence of *Prototheca zopfii* in bovine mastitis
J. Löffler, H. Einsele, H. Hebart, L. Hagmeyer, S. Kelly, G. Daum.
Analysis of plasma membranes of azole-resistant *Candida albicans* strains
A. B. Macura, A. Gniadek.
The occurrence of fungi in the environment and in the inmates of a social welfare home
A. B. Macura, B. Pawlik.
The *in vitro* susceptibility of moulds to recent antifungal drugs
R. Maleszka, Z. Adamski, G. Dworacki.
Evaluation of lymphocyte subpopulations and NK cells in peripheral blood of patients treated due to dermatophyte onychomycosis
J. Meletiadis, J. F. G. M. Meis, J. W. Mouton, G. S. De Hoog, R. Horre, P. E. Verweij.
In vitro activity of antifungal agents against pathogenic dematiaceous fungi of the genera *Exophiala* and *Ochroconis*
J. Meletiadis, J. W. Mouton, J. F. G. M. Meis, P. E. Verweij.
Comparison of the reproducibility of visual or spectrophotometric reading for the *in vitro* susceptibility testing of filamentous fungi
A. K. Mirzabalayeva, N. N. Klimko, N. D. Yarobkova.
Wobenzym in complex therapy of actinomycosis of abdominal cavity and small pelvis in women
F. A. Mühlschlegel, M. Frosch.
The relevance of *Candida* species other than *Candida albicans* as opportunistic pathogens
T. Nagy, J. Zala.
How to make good use of FUNID for yeast identification

P. Nenoff, U. Oswald, U.-F. Haustein.
In vitro susceptibility testing of fluconazole and itraconazole against different yeasts species and genus: evaluation of a microdilution assay
P. Nenoff, S. Kellermann, G. Borte, W. Pönisch, J. Winkler, R. Schober, U.-F. Haustein.
Pulmonary nocardiosis with cutaneous involvement under the picture of a metastasizing bronchoalveolar carcinoma occurring in a patient with chronic myelogenous leukaemia
A. Penk, L. Pittrow.
Otorhinolaryngologic fungal infections (OFI): possible role of fluconazole
A. Penk, L. Pittrow.
Role of long-term suppressive therapy after fungal infections of artificial implants (FIAI)
A. Penk, L. Pittrow.
Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients
A. Penk, L. Pittrow.
Therapeutic experience with fluconazole in the treatment of fungal infections in neurosurgery
L. Pittrow, A. Penk.
Pharmacokinetic peculiarities of fluconazole in special patient populations: septic, obese and burn patients
A. Plath, I. Vennewald, H. Porst, C. Seebacher.
The detection of fungal species in bronchoalveolar lavage fluid (BALF)
C. Raes-Wuytack, A. Willems, K. Van Looveren, M. Van Esbroeck, T. Vervoort, D. Swinne.
In vitro susceptibility of South American *Cryptococcus neoformans* isolates to amphotericin B, 5-fluorocytosine, fluconazole and itraconazole
C. Rimaroli, T. Bruzzese.
In vitro activity of SPA-S-843 against filamentous fungi
G. Reboux, A. Madroszyk, L. Millon, A. Depierre, J.-C. Dalphin, R. Piarroux.
Interest of antigens extracted from hay's microorganisms for farmer's lung diagnostic
D. Rimek, I. Kluge, R. Kappe.
Frequency of fungal colonization and invasive infection detected by conventional methods and a universal fungal PCR assay
C. Romano, F. Asta, L. Massai.
Cutaneous phaeohyphomycosis due to *Cladosporium oxysporum*
F. Romanyuk, V. Alferov, T. Bogomolova, V. Ilyina, S. Ignatieva.
Clinical characters and outcomes of chronic mucocutaneous candidosis
F. Romanyuk, V. Alferov, T. Bogomolova, S. Ignatieva, V. Ilyina.
Septic mycosis in children
M. Ruhnke, F.-M. Müller, U. Schneider, A. Adler.
Replacement of fluconazole-resistant *Candida albicans* strains by fluconazole-sensitive strains after initiation of HAART therapy for HIV infection
M. Ruhnke, C. Radecke, I. Grosch-Wörner, J. Morschhäuser.
Longitudinal study on the epidemiology of *Candida dubliniensis* in Berlin, Germany
M. Ruhnke, C. Radecke, T. Michalsky, M. Trautmann.
Investigation of a cluster of *Candida* peritonitis by using PCR genotyping
N. S. Ryder, I. Leitner.
Synergistic activity of terbinafine and azoles against drug-resistant *Candida* isolates
A. F. Schmalreck, W. Fegeler.
Standardisation of yeast susceptibility testing: Muticentre MIC-study to determine culture medium performance
A. F. Schmalreck, I. Kottmann, A. Reiser, P. Tränkle, E. Vanca.
Modification of recommended media for improved susecptibility testing of fluconazol (FCA), voriconazol (VOR) and itraconazol (ITR) against yeasts
G. Schröder, H. Bernhardt, K. Zimmermann, F. Feyerherd.
Post-traumatic wound infection caused by *Aspergillus flavus* and *Absidia corymbifera* in a non-immunocompromised host

M. Schröder, M. Kretschmar, T. Nichterlein, H. Hof.
Gastrointestinal candidiasis in mice
Ch. Schröter, U.-C. Hipler, A. Wilmer, U. Wollina.
Measurement of reactive oxygen species generated by *Candida albicans* using chemiluminescence and cytochrome assay
Ch. Schröter, U.-C. Hipler, U. Wollina.
Inhibitory effect of terbinafine on reactive oxygen species generated by *Candida albicans*
D. Senczek, B. Krüger, K. H. Böhm, U. Siesenop.
Characterisation of 220 *Malassezia* spp. isolated from animals
N. V. Shabashova, E. V. Frolova, A. K. Mirsabajaeva, A. E. Uchevatkina.
Proinflammatory cytokine expression in vaginal fluid in women with recurrent vulvovaginitis caused by *Candida albicans* and *Chlamydia* agents
H.-C. Sigle, M. Schäfer-Korting.
Detection of reactive oxygen species in *Candida albicans*
M. Skořepová.
Characteristics of *Candida* isolates from healthy blood donors and patients of intensive care units
A. Sobolev, N. Vasilyeva, T. Bogomolova, V. Mitrofanov.
Peculiarities of the clinical course of bronchial asthma in relation to ecological characteristics of patients' dwellings
A. Spreer, C. Schoen, U. Reichard, K. Vieluf, R. Rüchel.
Extracellular protenases of *Rhizopus microsporus*: role in blood coagulation during zygomycosis?
K. Süß, J. Schönlebe, C. Seebacher.
Cutaneous cryptococcosis in a woman with a long-term prednisolon therapy: a case report
S. Sundar, T. K. Jha, C. P. Thakur, M. Mishra, V. P. Singh, R. Buffels.
Efficacy and safety of liposomal amphotericin B (AmBisome) in the treatment of antimonial resistant visceral leishmanias
I. Török, G. Simon, B. Podányi, G. Stehlich.
Fluconazole treatment of superficial dermatophyte infections
A. Tomsiková.
Skin manifestation of some deep mycoses
Th. Treu, M. Knoch, U. Holl.
Results of mycological surveillance of long-term ventilated ICU-patients during five years
L. Turin, A. Poli, F. Riva, L. Bonizzi.
Nested PCR to detect dermatophytes in human and veterinary clinical specimens
N. Vasilyeva, N. Klimko, S. Khrypov, T. Bogomolova, G. Gorschkova, R. Araviyskiy, I. Vybornova.
Osteomyelitis of the right hip caused by *Sporothrix schenckii* after endoprosthesis of the coxo-femoral joint
A. Velegraki, V. G. Kiosses, A. Kansouzidou, E. Pitsouni, A. Mitroussia-Ziouva, V. D. Daniilidis, N. J. Legakis.
Rapid identification of *Cryptococcus neoformans* serotypes by PCR-REA from pure cultures and clinical samples. First report of *Cryptococcus neoformans* var. *gattii* infections in Greece
V. Vidotto, C. Y. Koga-Ito, A. Garramone, J. Pontón, G. Quindós, S. Aoki.
Virulence factors, serotype distribution and adherence in *Candida albicans*
M. Weig, M. Frosch, K. Haynes, F. A. Mühlschlegel.
CGG 1–3, a family of cell surface proteins in *Candida glabrata* essential for the cell wall
A. Wilke, P. C. Kemp, H. G. Neumeister-Kemp.
A relationship between airborne fungi and bacteria with suspended particulates, VOCs and odours before, on, and after the air filters of a HVAC system in a non-complaint building
G. Wozel, M. Thiele.
Evaluation of anti-inflammatory activity of different azole antifungals in arachidonic acid: induced mouse ear swelling test (MEST)
Ş. T. Yildiran, M. A. Saraçli, A. Gönlüm, H. Gün.
Isolation of *Cryptococcus neoformans* var. *neoformans* from pigeon droppings collected throughout Turkey
J. Zala, Zs. Gálffy, K. Kiss, T. Nagy, B. Frigy, J. Jákics, A. Telekes.
Problems in the antimycotic susceptibility of the fungal isolates; the influence of the therapy and other factors

Issue 4

225–230 **A. K. Gupta, S. B. S. Mann, V. K. Khosla, K. V. S. S. R. K. Sastry, J. S. Hundal.**
Nonrandomised comparison of surgical modalities for paranasal sinus mycoses with intracranial extension
Nicht-randomisierter Vergleich chirurgischer Maßnahmen bei Nebenhöhlenmykosen mit intrakranialer Ausbreitung

231–237 **D. Swinne, C. Raes-Wuytack, K. Van Looveren, P. Desmet.**
Comparative evaluation of Fungitest®, Neo-Sensitabs® and M27T-NCCLS broth microdilution methods for antifungal drug susceptibility testing of *Candida* species and *Cryptococcus neoformans*
Vergleichende Bewertung von Fungitest®, Neo-Sensitabs® und M27T-NCCLS Bouillon-Mikroverdünnungsmethoden zur Empfindlichkeitsprüfung von *Candida*-Arten und *Cryptococcus neoformans*

239–247 **E. Chryssanthou, L. Klingspor, J. Tollemar, B. Petrini, L. Larsson, B. Christensson, O. Ringdén.**
PCR and other non-culture methods for diagnosis of invasive *Candida* infections in allogeneic bone marrow and solid organ transplant recipients
PCR und andere Nichtkulturmethoden zur Diagnose invasiver *Candida*-Infektionen bei Empfängern von allogenem Knochenmark und soliden Organtransplantaten

249 253 **A. H. Aubaid, A. Z. Risan, A. K. Naem.**
Detection of sugars and aminoacids in antigens of *Trichophyton mentagrophytes* var. *erinacei*
Zucker- und Aminosäurengehalt in Antigenen von *Trichophyton mentagrophytes* var. *erinacei*

255–259 **C. A. Lyman, E. Navarro, K. F. Garrett, D. D. Roberts, P. A. Pizzo, T. J. Walsh.**
Adherence of *Candida albicans* to bladder mucosa: development and application of a tissue explant assay
Entwicklung und Anwendung eines Gewebs-Explant Assays zur experimentellen Untersuchung der Adhärenz von *Candida albicans* an Urothelzellen

261–264 **B. R. Gedek.**
Adherence of *Escherichia coli* serogroup 0 157 and the *Salmonella typhimurium* mutant DT 104 to the surface of *Saccharomyces boulardii*
Adhärenz von *Escherichia coli* Serogruppe 0 157 und von der *Salmonella Typhimurium*-Mutante DT 104 an der Oberfläche von *Saccharomyces boulardii*

265 267 **G. P. Panagoda, L. P. Samaranayake.**
A new, semi-automated technique for quantification of *Candida* adherence to denture acrylic surfaces
Eine neue, halbautomatische Methode zur quantitativen Erfassung der *Candida*-Adhärenz an zahnmedizinischen Akryloberflächen

269–277 **A. Plettenberg, A. Stoehr, W. Heise, F. Schlote, E. Sarnow, M. Migdal.**
Efficacy, safety and toleration of fluconazole suppositories in the treatment of oral candidosis
Wirksamkeit, Verträglichkeit und Akzeptanz von Fluconazol-Suppositorien bei der Behandlung der oralen Candidose

273 279 **J. Moulin-Traffort, M.-D. Steinmetz, J. -P. Rascol, P. Regli.**
Effects of *Pycnoporellus fulgens* (Fr.) Donk crude extract on *Candida glabrata* ultrastructure
Veränderungen der *Candida glabrata*-Ultrastruktur durch Rohextrakt von *Pycnoporellus fulgens* (Fr.) Donk

281–283 **Cintia de Moraes Borba, M. de Nazareth Silveira, A. M. Mendes da Silva, P. Cunha de Oliveira.**
Ultrastructural differences observed in *Paracoccidioides brasiliensis* yeast phase cells grown on solid and in liquid medium
Ultrastruktur-Unterschiede bei *Paracoccidioides brasiliensis* in der Hefephase, angezüchtet auf festen und in flüssigen Nährmedien

285–289 **O. Ayeni, K. M. Riederer, F. M. Wilson, R. Khatib.**
Clinicians' reaction to positive urine culture for *Candida* yeasts
Kliniker-Reaktionen auf *Candida*-positive Urinbefunde

291 296 **C. L. Feio, L. Bauwens, D. Swinne, W. de Meurichy.**
Isolation of *Basidiobolus ranarum* from ectotherms in the Antwerp zoo with special reference to characterization of the isolated strains
Charakterisierung von *Basidiobolus ranarum*—Isolaten aus wechselwarmen Tieren des Antwerpener Zoos

297–305 **F. Seneczko, S. Lupa, J. Jeske, A. Głowacka, A. Ochecka-Szymańska.**
Epidemiology of dermatomycoses of humans in Central Poland. Part I. Superficial infections caused by yeasts and moulds
Epidemiologie humaner Dermatomykosen in Zentral-Polen. Teil I. Oberflächliche Infektionen durch Hefen und Schimmelpilze

307–310 **F. Seneczko, J. Jeske, S. Lupa, A. Głowacka, A. Ochecka-Szymańska.**
Epidemiology of dermatomycoses of humans in Central Poland. Part II. Non-dermatophyte infections of nails and periungal walls
Epidemiologie humaner Dermatomykosen in Zentral-Polen. Teil II. Nicht-Dermatophyten-Infektionen an Nägeln und Nagelwällen

311–317 **K. H. Abu-Elteen.**
Incidence and distribution of *Candida* species isolated from human skin in Jordan
Inzidenz und Verteilung von *Candida*-Arten, isoliert von menschlicher Haut in Jordanien

319–322 **T. Koussidou-Eremondi, D. Devliotou-Panagiotidou, O. Mourellou-Tsatsou, D. Fotidou, A. Minas.**
Tinea capitis in children in Northern Greece during the period 1981–1995
Tinea capitis bei Kindern in Nord-Griechenland 1981-1995

323–329 **Y. Yegenoglu, M. Kiraz, Z. Erturan, Ö. Ang.**
The epidemiology of onychomycoses in Istanbul, Turkey
Die Epidemiologie der Onychomykosen in Istanbul, Türkei

331 333 **A.-H. Al Duboon, T. H. Muhsin, K. K. Al-Rubaiy.**
Tinea capitis in Basrah, Iraq
Tinea capitis in Basrah, Irak

335 338 **T. M. Muhsin, K. K. Al-Rubaiy, A.-H. A. Al-Duboon.**
Characteristics of dermatophytoses in Basrah, Iraq
Charakteristika von Dermatophytosen in Basrah, Irak

339–343 **A. H. Bahkali, S. Parvez.**
Fungal flora in the house dust in Riyadh, Saudi Arabia
Mykoflora im Hausstaub in Riyadh, Saudi-Arabien

345 346 **G. Sentamilselvi, C. Janaki, V. R. Janaki, S. Devesh, K. Ajitados.**
Eumycetoma due to *Curvularia lunata*
Fallbericht. Eumyzetom verursacht durch *Curvularia lunata*

347 349 **R. López-Martínez.**
Cutaneous penicilliosis due to *Penicillium chrysogenum*
Fallbericht. Penicilliose der Haut durch *Penicillium chrysogenum*

Issue 5/6

355–370 **A. Polak.**
The past, present and future of antimycotic combination therapy
Vergangenheit, Gegenwart und Zukunft der antimykotischen Kombinationstherapie

371–383 **A. Lischewski, D. Harmsen, K. Wilms, G. Baier, U. Gunzer, H. Klinker, M. Wilhelm, A. Schwinn, J. Hacker.**
Molecular epidemiology of *Candida albicans* isolates from AIDS and cancer patients using a novel standardized CARE-2 DNA fingerprinting technique
Molekulare Analyse klinischer *Candida albicans* Isolate von AIDS- und Krebspatienten mittels standardisierter Fingerprint-Technik

385–394 **M. Ruhnke, I. Grosch-Wörner, A. Lischewski, A. Neubauer, A. Steinmüller, M. Trautmann, J. Morschhäuser.**
Genotypic relatedness of yeast isolates from women infected with human immunodeficiency virus and their children
Genotypische Verwandtschaft der Hefeisolate von HIV-infizierten Frauen und ihren Kindern

395–402 **A. Glasmacher, C. Hahn, E. Molitor, T. Sauerbruch, I. G. H. Schmidt-Wolf, G. Marklein.**
Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia
Pilznachweis in Überwachungskulturen während der antimykotischen Prophylaxe mit Itraconazol bei neutropenischen Patienten mit akuter Leukämie

403–408 **A. J. Barnes, B. A. Oppenheim, J. Chang, G. R. Morgenstern, J. H. Scarffe.**
Early investigation and initiation of therapy for invasive pulmonary aspergillosis in leukaemic and bone marrow transplant patients
Frühdiagnose und Frühtherapie der invasiven Lungenaspergillose bei Leukämie- und Knochenmarktransplantationspatienten

409–414 **D. Senczek, U. Siesenop, K. H. Böhm.**
Characterization of *Malassezia* species by means of phenotypic characteristics and detection of electrophoretic karyotypes by pulsed-field gel electrophoresis (PFGE)
Charakterisierung von *Malassezia* spp. anhand phänotypischer Eigenschaften und Darstellung der Kernverhältnisse mittels Pulsfeldgelelektrophorese (PFGE)

415–420 **R. Schopf, O. Hettler, M. Bräutigam, G. Weidinger, U. Kaben, P. Mayser, V. Resl.**
Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared to 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: a randomized, double-blind, multi-center, 8-week clinical trial
Wirksamkeit und Verträglichkeit einer einwöchigen Therapie mit 1%iger Terbinafin-Lösung im Vergleich zu einer vierwöchigen Therapie mit 1%iger Clotrimazol-Lösung in der Behandlung der interdigitalen Tinea pedis: Eine randomisierte, doppel-blinde, multizentrische, achtwöchige klinische Studie

421–425 **C. Romano.**
Four paediatric cases of tinea capitis due to unusual agents
Fallberichte: Vier pädiatrische Falle von Tinea capitis mit ungewöhnlichen Erregern

427–430 **D. Kurzai, W. J. Heinz, F. A. Mühlschlegel.**
ASM-Conference '*Candida* and Candidiasis'. March 1–4, 1999. Charleston SC, USA
ASM-Conference '*Candida* and Candidiasis'. 1.-4. März 1999. Charleston SC, USA

Issue 7–8

431–442 **A. H. Groll, M. Kurz, W. Schneider, V. Witt, H. Schmidt, M. Schneider, D. Schwabe.**
Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management, and long-term survival
Invasive Aspergillosen in einer pädriatrisch-onkologischen Abteilung. Epidemiologie, Behandlung und Langzeit-Überleben

443–451 **A. Glasmacher, C. Hahn, C. Leutner, E. Molitor, E. Wardelmann, C. Losem, T. Sauerbruch, G. Marklein, I. G. H. Schmidt-Wolf.**
Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole
Invasive Mykosen bei neutropenischen Patienten nach Prophylaxe mit Itraconazol

453–458 **R. Franz, M. Ruhnke, J. Morschhäuser.**
Molecular aspects of fluconazole resistance development in *Candida albicans*
Molekulare Aspekte der Fluconazol-Resistenzentwicklung in *Candida albicans*

459–463 **G. Inselmann, A. Schimanski, R. Jahns, H. T. Heidemann.**
Liposomal amphotericin B (AmBisome®) application and hepatic microsomal enzyme function in the rat
Liposomales Amphotericin B (AmBisome®): Einfluß auf die Leberenzymfunktionen in der Ratte

465–474 **R. Giordani, C. Gachon, J. Buc, P. Regli, J. L. Jacob.**
Antifungal action of *Hevea brasiliensis* latex. Its effects in combination with fluconazole on *Candida albicans* growth
Die antimyzetische Wirkung von *Hevea brasiliensis*-Latex in Kombination mit Fluconazol auf das Wachstum von *Candida albicans*

475–478 **K. M. Brocks, U. B. Johansen, H. O. Jorgensen, L. Reymann Ravnborg, E. Lyngsøe Svejgaard.**
Tinea pedis and onychomycosis in Danish soldiers before and after service in ex-Yugoslavia
Tinea pedis und Onychomykosen bei dänischen Soldaten vor und nach ihrem Einsatz in Ex-Jugoslawien

479–484 **H. Noguchi, M. Hiruma, A. Kawada.**
Effectiveness of treatment of severe tinea pedis with 1% terbinafine cream in members of the Japanese Self-Defense Forces
Wirksamkeit der Behandlung schwerer Tinea pedis mit 1%iger Terbinafin-Creme bei Mitgliedern der Japanischen Selbstverteidigungs-Streitkräfte

485–493 **G. Müller, P. Kielstein, H. Rosner, A. Berndt, M. Heller, H. Köhler.**
Studies on the influence of combined administration of ochratoxin A, fumonisin B1, deoxynivalenol and T2 toxin on immune and defence reactions in weaner pigs
Untersuchungen zur Beeinflussung von Immun- und Abwehrvorgängen durch kombinierte Applikationen von Ochratoxin A, Fumonisin B1, Deoxynivalenol und T2-Toxin an Läuferschweinen

495–505 **G. Müller, P. Kielstein, H. Rosner, A. Berndt, M. Heller, H. Köhler.**
Studies on the influence of ochratoxin A on immune and defence reactions in weaners
Untersuchungen zur Beeinflussung von Immun- und Abwehrvorgängen an Läuferschweinen durch Ochratoxin A

507–511 **G. Ginter, B. Petutschnig, G. Pierer, H. P. Soyer, S. Reischle, T. Kern, S. de Hoog.**
Case Report. Atypical cutaneous pseudallescheriosis refractory to antifungal agents
Fallbericht: Atypische therapierefraktäre kutane Pseudallescheriose

Issue 9/10

515–520 **M. A. Gabal, A. M. El-Sherif, M. S. Enany, S. S. Soliman.**
A polymerase chain reaction 'PCR' for a quick diagnosis of aspergillosis
Eine Polymerase-Ketten-Reaktion PCR zur Schnelldiagnose der Aspergillose

521–524 **P. Staib, J. Morschhäuser.**
Chlamydospore formation on Staib agar as a species-specific characteristic of *Candida dubliniensis*
Chlamydosporenbildung auf Staib-Agar als artspezifisches Merkmal von *Candida dubliniensis*

525 528 **J. Bastert, H. C. Korting, P. Traenkle, A. F. Schmalreck.**
Identification of dermatophytes by Fourier transform infrared spectroscopy (FT-IR)
Identifikation von Dermatophyten mittels Fourier-Transform-Infrarot-Spektroskopie (FT-IR)

529–538 **R. Kunze, B. Schütz, W. Schrödl, H. Bernhardt.**
Candida albicans clinical isolates inactivated by formalin with different adherence to buccal epithelial cells induce proinflammatory and regulatory cytokines in human peripheral blood monocellular cells
Formolinaktivierte klinische Isolat von *Candida albicans* mit unterschiedlichem Adhärenzverhalten an bukkale Epithelzellen induzieren proinflammatorische und regulatorische Zytokine in humanen mononukleären Zellen des peripheren Blutes

539–542 **C. A. Kauffman, L. T. Zarina.**
Colorimetric method for susceptibility testing of voriconazole and other triazoles against *Candida* species
Kolorimetrische Methode zur Empfindlichkeitsprüfung von Voriconazol und anderen Triazolen für *Candida*-Arten

543–548 **C. Farina, F. Vailati, A. Manisco, A. Goglio.**
Fungaemia survey. A 10-year experience in Bergamo, Italy
Fungämien der letzten 10 Jahre in Bergamo, Italien

549–554 **D. Mares, C. Romagnoli, G. Sacchetti, C. B. Vicentini, A. Bruni.**
Alterations in spore production in *Trichophyton rubrum* treated *in vitro* with 1-amino-6-methyl-4-phenylpyrazol-[3,4-d]-1,2,3-triazole
Veränderungen der Sporenbildung *in vitro* an 1-Amino-6-methyl-4-phenylpyrazol-[3,4-*d*]-1,2,3-triazol behandeltem *Trichophyton rubrum*

555–558 **M. Binder, G. Nell.**
Oral terbinafine (Lamisil®) in the short-term treatment of fungal infections of the skin. Results of a postmarketing suveillance study
Kurzzeitbehandlung oberflächlicher Pilzinfektion der Haut mit oralem Terbinafin : Ergebnisse einer 'Post-marketing Surveillance'-Studie

559–562 **C. Romano.**
Tinea capitis in Siena, Italy. An 18-year survey
Tina capitis in Siena, Italien. Retrospektive Analyse der letzten 18 Jahre

563–565 **S. Lupa, F. Seneczko, J. Jeske, A. Głowacka, A. Ochecka-Szymańska.**
Epidemiology of dermatomycoses of humans in Central Poland. Part III. Tinea pedis
Epidemiologie humaner Dermatomykosen in Zentralpolen. Teil III. Tinea pedis

567–569 **S. Cimerman, W. Sokolowski, S. E. C. Gonçalves, M. Soares de O Lins, A. L. Colombo.**
Case Report. Histoplasmosis in an AIDS paediatric patient
Fallbericht. Histoplasmose bei einem Kind mit AIDS

571–576 **H. Noguchi, M. Hiruma, A. Kawada.**
Case report. Sporotrichosis sucessfully treated with itraconazole in Japan
Fallbericht. Intraconazol-behandelte Sporotrichose in Japan

577–580 **H.-J. Tietz, V. Czaika, W. Sterry.**
Case report. Osteomyelitis caused by high-grade resistant *Candida guilliermondii*
Fallbericht. Osteomyelitis verursacht durch hochgradig resistente *Candida guilliermondii*

581–585 **H. Tanuma, M. Doi, M. Abe, H. Kume, S. Nishiyama, K. Katsuoka.**
Case Report. Kerion Celsi effectively treated with terbinafine. Characteristics of kerion Celsi in the elderly in Japan
Fallbericht. Erfolgreich mit Terbinafin behandeltes Kerion Celsi. Charakteristik des Kerion Celsi bei älteren Patienten in Japan

587–589 **S. Veraldi, A. Gorani, E. Schmitt, R. Gianotti.**
Case Report. Tinea corporis purpurea
Fallbericht. Tinea corporis purpurea

Issue 11–12

591–600 **A. Glasmacher, C. Hahn, E. Molitor, G. Marklein, T. Sauerbruch, I. G. H. Schmidt-Wolf.**
Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-β-cyclodextrin oral solution or coated-pellet capsules
Itraconazol-Talspiegel unter antimykotischer Prophylaxe mit sechs verschiedenen Dosierungen von Hydroxy-β-Cyclodextrin-Lösung oder Coated-Pellet-Kapseln

601–608 **G. Criseo, M. Gallo, A. Pernice.**
Killer activity at different pHs against *Cryptococcus neoformans* var. *neoformans* serotype A by environmental yeast isolates
Killeraktivität bei unterschiedlichem pH gegen *Cryptococcus neoformans* var. *neoformans* Serotyp A durch Hefe-Umgebungsisolate

609–614 **R. B. Caligiorne, M. A. de Resende, E. Dias-Neto, S. C. Oliveira, V. Azevedo.**
Dematiaceous fungal pathogens: analysis of ribosomal DNA gene polymorphism by polymerase chain reaction-restriction fragment length polymorphism
Schwärzepilz-Erreger: Analyse ribosomaler DNS-Gen-Polymorphismen mittels PCR-RFLP

615–617 **S. Rezaie, M. Pourmojib, E. Tschachler.**
Isolation of total RNA from dermatophytes
Isolierung der Gesamt-RNA aus Dermatophyten

619–627 **C. Hermann, J. Hermann, U. Munzel, R. Rüchel.**
Bacterial flora accompanying *Candida* yeasts in clinical specimens
Bakterielle Begleitflora von klinischen *Candida*-Isolaten

629–639 **P. Nenoff, U. Oswald, U.-F. Haustein.**
In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test
In vitro-Empfindlichkeit von Sproßpilzen für Fluconazol und Itraconazol. Bewertung eines Mikrodilutionstestes

641–644 **J. C. P. de Resende, M. A. de Resende.**
In vitro antifungal susceptibility of clinical isolates of *Candida* spp. from hospitalized patients
Die Antimykotika-Empfindlichkeit *in vitro* klinischer *Candida*-Isolate von Krankenhauspatienten

645–647 **R. Willemsen, J. Breynaert, S. Lauwers.**
The influence of alcohol disinfection of nail samples in the laboratory
Der Einfluß der Alkoholdesinfektion von Nagelproben im Labor

649–655 **A. del Palacio, S. Cuétara, A. Pérez, M. Garau, T. Calvo, G. Sánchez-Alor.**
Topical treatment of dermatophytosis and cutaneous candidosis with flutrimazole 1% cream: double-blind, randomized, comparative trial with ketoconazole 2% cream
Topische Behandlung von Dermatophytosen und kutaner Candidose: Doppelblinde, randomisiert Vergleichsstudie mit 1%iger Flutrimazol-Creme versus 2%iger Ketoconazol-Creme

657–659 **S. Lupa, F. Seneczko, J. Jeske, A. Głowacka, A. Ochecka-Szymańska.**
Epidemiology of dermatomycoses of humans in Central Poland. Part IV. Onchomycosis due to dermatophytes.
Epidemiologie humaner Dermatomykosen in Zentralpolen. Teil IV. Dermatophyten-bedingte Onchomykosen

661–663 **J. Jeske, F. Seneczko, S. Lupa, A. Głowacka, A. Ochecka-Szymańska.**
Epidemiology of dermatomycoses of humans in Central Poland. Part V. Tinea corporis
Epidemiologie humaner Dermatomykosen in Zentralpolen. Teil V. Tinea corporis

665–672 **M. S. Ali-Shtayeh, S. I. Abu Ghdeib.**
Antifungal activity of plant extracts against dermatophytes
Antimyzetische Aktivität von Pflanzenextrakten gegen Dermatophyten

673–674 **E. Guého, J. Guillot.** Comments on *Malassezia* species from dogs and cats
Kommentar zu *Malassezia*-Arten bei Hunden und Katzen

675 677 **S. Yokoi, T. Iizasa, S. Yoshida, K. Kamei, K. Hiroshima, O. Ohwada, T. Fujisawa.**
Case report. Localized pulmonary zygomycosis without pre-existing immunocompromised status
Fallbericht. Lokalisierte Zygomykose der Lunge ohne bestehende Immunschwäche

679–682 **Y. Zhirong, L. Wanqing, P. Weihua.**
Case reports. Invasive pulmonary aspergillosis in non-neutropenic patients treated with liposomal amphotericin B
Fallberichte. Invasive Lungenaspergillose bei Nicht-Neutropenikern erfolgreich mit liposomalem Amphotericin B behandelt

683–685 **K. Süß, I. Vennewald, C. Seebacher.**
Case Report. Folliculitis barbae due to *Candida albicans*
Fallbericht. Folliculitis barbae candidomycetica

Supplement 1

1–2 **J. Müller und M. Knoke.**
Das 7. Greifswalder Colloquium Mycologicum

3–4 **J. Müller.**
Laudatio für Frau Professor Hannelore Bernhardt

5–11 **J. Müller.**
Candida albicans im elektronenoptischen Bild
Candida albicans in electronmicroscopical presentation

12–21 **F. Schaufer und R. Hanschke.**
Zur Taxonomie und Ökologie der Gattung *Candida*
Taxonomy and ecology of the genus *Candida*

22–29 **Renate Blaschke-Hellmessen.**
Standorte für *Candida* aus medizinisch-hygienischer Sicht
Habitats for *Candida* in medical and hygienic respects

30–34 **M. Knoke.**
Gastrointestinale Mikroökologie des Menschen und *Candida*
Gastrointestinal microecology of humans and *Candida*

35 38 **R. S. Jack und Wiegand.**
Analyse des „Innate"-Immunsystems
Analysis of the „innate" immune system

39 42 **F.-M. C. Müller, J. Morschhäuser, G. Köhler, T. A. Oelschlaeger, W. Ziebuhr und J. Hacker.**
Adhärenz und Invasion: Zwei Pathogenitätsfaktoren bei pathogenen Bakterien und Pilzen
Adherence and invasion – two pathogenicity factors in bacterial and fungal pathogens

43–47 **A. Wellmer.**
Adhärenz von klinischen *Candida albicans*-Isolaten an bukkalen Epithelzellen
Adherence of clinical *Candida albicans* isolates to buccal epithelial cells

48–52 **R. Rüchel.**
Proteinasen pathogener Pilze
Proteinases of pathogenic fungi

53–59 **F. Kroschynski, R. Naumann, G. Ehninger.**
Candida-Mykosen in der Hämatologie/Onkologie. Aspekte zu Epidemiologie, Diagnostik, Prophylaxe und Therapie
Candida mycoses in hematology/oncology. Aspects of epidemiology, diagnosis, prophylaxis and treatment

60–62 **G. Schwesinger.**
Disseminierte Candidose bei frühgeborenen Zwillingen. Fallbericht
Disseminated candidosis in premature twins. Case report

63–67 **C. Seebacher.**
Candida in der Dermatologie
Candida in dermatology

68–72 **J. Bernhardt.**
Candidosen im Oro intestinaltrakt unter besonderer Berücksichtigung des Ösophagus
Orointestinal candidosis with special regard of the oesophagus

73–79 **J. Bastert und H. C. Korting.**
Molekulare Grundlagen der antimykotischen Therapie
Molecular basis of antimycotic therapy

Supplement 2

1 **J. Müller.**
Obituary Edouard Drouhet

3 **J. Müller and H. Bernhardt.**
The 5th ECMM Congress 1999 in Dresden

5 **J. Müller.**
Forschungsförderpreis 1999 of the Deutschprachige Mykologische Gesellschaft

6 **J. Müller.**
Obituary Luise Krempl-Lamprecht

7–10 **E. C. M. Williamson and J. P. Leeming.**
Molecular approaches for the diagnosis and epidemiological investigation of *Aspergillus* infection
Molekularbiologische Studien zur Diagnose und Epidemiologie der *Aspergillus*-Infektion

11–18 **E. Drouhet and M. Huerre.**
Yeast tissue phase of *Emmonsia pasteuriana* inoculated in golden hamster by intratesticular way
Gewebschefephase von *Emmonsia pasteuriana* nach intratestikulärer Infektion von Goldhamstern

19–24 **Marianne Kretschmar, T. Bertsch, M. Göller, M. Schaller, H. Hof and T. Nichterlein.**
Parameters for determination of *C. albicans* virulence in murine peritonitis

25 28 **Dagmar Rimek, T. Zimmermann, M. Hartmann, Chularut Prariyachatigul and R. Kappe.**
Disseminated *Penicillium marneffei* infection in an HIV-positive female from Thailand in Germany
Disseminierte *Penicillium marneffei*-Infektion bei einer HIV-infizierten Thailänderin in Deutschland

29 32 **Hannelore Bernhardt, Kathrin Zimmermann and M. Knoke.**
The continuous flow culture as an in vitro model in experimental mycology
Die kontinuierliche Kultur als ein in vitro Modell in der experimentellen Mykologie

33 36 **Irina Vennewald, M. Henker, E. Klemm and C. Seebacher.**
Fungal colonization of the paranasal sinuses
Zum Pilznachweis in den paranasalen Sinus

37–43 **J. W. Murphy.**
Immunological down-regulation of host defenses in fungal infections
Immunologische Herabregulierung der Wirtsabwehr bei Pilzinfektionen

45–48 **L. Romani.**
Cytokine modulation of specific and nonspecific immunity to *Candida albicans*
Cytokin-Modulation der spezifischen und unspezifischen Immunität gegen *Candida albicans*

49–53 **J. A. Calera and R. Calderone.**
Histidine kinase, 2 component signal transduction proteins of *Candida albicans* and the pathogenesis of candidiasis
Histidinkinase, Zwei-Komponenten-Signaltransduktionsproteine von *Candida albicans* und die Candidose-Pathogenese

55–59 **E. Segal.**
Experimental candidosis. pathogenesis, prevention, therapy
Experimentelle Candidose: Pathogenese, Prävention, Therapie

61–67 **M. R. Weide and J. F. Ernst.**
Caco-2 monolayer as a model for transepithelial migration of the fungal pathogen *Candida albicans*
Caco-2-Monolayer als Modell fur die transepitheliale Migration von *Candida albicans*

69–72 **F.-M. C. Müller, A. Lischewski, D. Harmsen and J. Hacker.**
Standardized molecular typing
Standardisierung der molekularen typisierung

73–76 **H.-J. Tietz, V. Czaika, H. M. Ulbricht and W. Sterry.**
Tinea capitis in Germany. A survey in 1988
Tinea capitis in Deutschland. Eine prospektive Analyse 1998

77–82 **F.-M. C. Müller, C. A. Lyman and T. J. Walsh.**
Antimicrobial peptides as potential new antifungals
Antimikrobielle Peptide als mögliche neue Antimykotika-Substanzklasse

83–86 **R. Kappe.**
Antifungal activity of the new azole UK-109,496 (voriconazole)

87–90 **L. Pittrow and A. Penk.**
Special pharmacokinetics of fluconazole in septic, obese and burn patients
Spezielle Pharmakokinetik von Fluconazol bei Patienten mit Sepsis, Adipositas und Verbrennungstrauma

91–96 **A. Penk and L. Pittrow.**
Role of long-term suppressive therapy after fungal infections of artificial implants (FIAI)
Stellenwert von Fluconazol in der Langzeitsuppressionstherapie von Pilzinfektionen künstlicher Implantate

97–100 **A. Penk and L. Pittrow.**
Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients
Therapieerfahrungen mit Fluconazol in der Behandlung von Pilzinfektionen diabetischer Patienten

101–104 **G. Silling, W. Fegeler, N. Roos, M. Essink and T. Büchner.**
Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/5-flucytosine
Vergleich von Fluconazol und Amphotericin B/5-Flucytosin in der frühen empirischen antimykotischen Therapie von Infektionen bei neutropenischen Patienten

105–110 **M. C. Bradley, S. Leidlich, N. Isham, B. E. Elewski and M. A. Ghannoum.**
Antifungal susceptibilities and genetic relatedness of serial *Trichophyton rubrum* isolates from patients with onychomycosis of the toenail
Antimyzetika-Empfindlichkeit und genetische Verwandtschaft sequentieller *Trichophyton rubrum*-Isolate von Patienten mit Zehennagel-Onychomykose

111–114 **A. Pérez.**
Terbinafine: broad new spectrum of indications in several subcutaneous and systemic mycoses and parasitic diseases
Terbinafin: Breites neues Indikationsspectrum bei verschiedenen subkutanen und systemischen Mykosen und Parasitosen

115–119 **N. S. Ryder.**
Activity of terbinafine against serious fungal pathogens
Terbinafin-Aktivität gegen bedeutende Mykose-Erreger

121–124 **C. C. Kibbler.**
Antifungal prophylaxis with itraconazole oral solution in neutropenic patients
Antimzetische Prophylaxe mit oraler Itraconazol-Lösung bei neutropenischen Patienten

SUBJECT INDEX

A

α-amylase 19 (S2)
action mechanism 73 (S1)
adherence 255, 261, 265, 529, 39 (S1), 43 (S1)
AIDS 41, 117, 567
alanine-aminotransferase 19 (S2)
allylamines 415, 479, 555, 581, 105 (S2), 111 (S2), 115 (S2)
AmBisome® 47, 117, 459
Amphotericin B 459, 567, 641, 101 (S2)
animal model 459, 485, 495, 11 (S2), 55 (S2)
antifungal action 465
antifungal activity 97, 665, 29 (S2), 77 (S2), 83 (S2)
antifungal drugs 641, 105 (S2), 111 (S2), 115 (S2)
antifungal prophylaxis 443, 591
antifungal susceptibility 55, 311, 115 (S2)
antigens 249
antigen-antibody reactions 5 (S1)
antimycotic chemotherapy 3, 21, 79, 93, 117, 269,355, 403, 415,431, 479, 507, 555, 567, 577, 581, 649, 679, 683, 53 (S1), 73 (S1), 55 (S2), 73 (S2), 87 (S2), 91 (S2), 97 (S2), 101 (S2), 111 (S2)
antimicrobial activity 77 (S2)
AP-PCR 385
army 479
arthroconidia 549
Arthroderma benhamiae 71
Arthroderma simii 71
Arthroderma vanbreuseghemii 71
Arthrodermataceae 67
artificial implants 91 (S2)
Aspergillus 7 (S2), 115 (S2)
aspergillosis 47, 403, 431, 443, 515, 679
atopic dermatitis 63 (S1)
azole antifungal 3, 17, 55, 79, 93, 269, 347, 395, 443, 453, 507, 567, 571, 577, 591, 629, 683, 25 (S2), 87 (S2), 91 (S2), 97 (S2), 101 (S2), 121 (S2), 124 (S2)

B

bacteria 619
bacterial lung defence 495
Basidiobolus ranarum 291
biofilm formation 37
bird droppings 601
bone marrow transplantation 53 (S1), 7 (S2)
breakthrough infections 443
burn patients 87 (S2)

C

Caco-2 61 (S2)
canary 601
cancer 431
Candida 55, 61, 231, 255, 265, 285, 311, 323, 385, 427, 539, 619, 641, 12 (S1), 22 (S1), 30 (S1), 29 (S2), 115 (S2)
Candida albicans 33, 37, 41, 311, 371, 453, 465, 529, 629, 683, 5 (S1), 22 (S1), 43 S1), 60 (S1), 63 (S1), 19 (S2), 45 (S2), 49 (S2), 61 (S2), 69 (S2),
Candida dubliniensis 29, 521
Candida glabrata 273, 33
Candida guilliermondii 577
Candida tropicalis 37
candidaemia 3, 17,
candidosis 3, 239, 269, 285, 311, 427, 577, 649, 53 (S1), 60 (S1), 68 (S1), 49 (S2), 55 (S2), 99 (S2)
candiduria 285
CARE-2 fingerprinting 29
CARE-2 hybridization 385
cats 673
CAVH 17
CAVHD 17
cell-mediated immunity 37 (S2)
child 567
children 319, 431
chitin synthase gene 71
chlamydospores 521, 549
CHROMagar Candida 61
chromoblastomycosis 609
Chrysosporium queenslandicum 107
Cladophialophora 609
Cladosporium oxysporum 111
clinical specimens 619
clotrimazole 1% solution 415
colonization 33 (S2)
colorimetric assay 539
combination therapy 355
Congress report 427
continuous flow culture 29 (S2)
creatinine assimilation 103
Cryptococcus 37 (S2)
Cryptococcus laurentii 103
Cryptococcus neoformans 103, 231, 601
Curvularia lunata 345
Cushing syndrome 111
cutaneous infection 111, 311, 347, 507, 649, 555
CVVH 17
CVVHD 17
cystic fibrosis 7 (S2)
cytokines 529, 45 (S2)

D

D/L-arabinitol ratio 239
dematiaceous fungi 609
Denmark 475
deoxynivalenol 485
dermatomycoses 297, 563, 657, 661, 63 (S1)
dermatophytes 67, 319, 323, 331, 335, 525, 615, 657, 665
dermatophytosis 649, 75
diabetics 97 (S2)
diagnosis 403, 515
differential display 35 (S1)
differentiation 67
dimorphism 61 (S2)
disinfection 645
dissemination 107, 60 (S1), 19 (S2)
DNA fingerprinting 453
DNA hybridization 69 (S2)
dosage 17, 87 (S2)
dogs 673
drug monitoring 17, 87 (S2)

E

ecology 12 (S1), 22 (S1)
ectotherms 291
EHEC 261
efg1 mutants 61 (S2)
elderly 581
electronmicroscopy 273, 281, 549, 5 (S2)
Emmonsia pasteuriana 11 (S2)
empiric therapy 101 (S2)
Enterobacter 619
environmental isolates 601
enzymes 291, 459
epidemiology 41, 75, 297, 307, 311, 319, 323, 331, 335, 339, 371, 431, 443, 453, 475, 543, 559, 563, 657, 661, 673, 7 (S2), 73 (S2)
Epidermophyton floccosum 421
epithelial cells 43 (S1)
Escherichia coli 261
essential oils 97
eumycetoma 345
experimental model 459, 485, 495, 11 (S2), 55 (S2)

F

fibronectin 37
fingerprint 371
fitness factors 39 (S1)

fluconazole 3, 17, 55, 79, 93, 269, 347, 395, 443, 453, 507, 567, 571, 577, 591, 629, 683, 25 (S2), 87 (S2), 91 (S2), 97 (S2), 101 (S2), 121 (S2), 124 (S2)
flucytosine 641, 101 (S2)
flurimazole 649
folliculitis barbae 683
Fonsecaea 609
Fourier transform
infrared spectroscopy 525
FT-IR 525
fumonisin 485
fungaemia 543
fungal flora 339
fungal infection 395, 443
fungi 48 (S1)
Fungitest® 231
Fusarium 97

G

garter snake 107
gastrointestinal tract 30 (S1)
genotypic analysis 371
Germany 73 (S2)
golden hamster 11 (S2)
Greece 319
Green colour effect (GCE) 103

H

habitat 22 (S1)
haemodialysis 17, 87 (S2)
haemofiltration 17, 87 (S2)
heart transplant 507
Hevea brasiliensis latex 465
histidin kinases 49 (S2)
histology 33 (S2)
histoplasmosis 117, 567
HIV 25 (S2)
HIV infection 385, 55
homologous recombination 35 (S1)
host defense 77 (S2)
host fungus interacations 5 (S1)
house dust 339
hyperkeratosis 21

I

identification 525, 61
immune system 529, 35 (S1)
immunity 45 (S2)
immunoelectronmicroscopy 5 (S1)
immunomodulation 485, 495
infants 3
inflammation response 35 (S1)
intensive care 68 (S1)
internal transcribed spacer (ITS) 67
intestinal colonization 63 (S1)
intracranial extension 225
intraperitoneal infection 19 (S2)
invasion 239, 39 (S1), 9 (S2)
Iraq 331, 335
isolation 61, 645
Italy 543, 559
itraconalzole oral solution 591
itraconazole 79, 93, 347, 395, 443, 507, 567, 571, 577, 591, 629, 641, 683, 25 (S2), 121 (S2), 124 (S2)
intratesticular inoculation 11, (S2)

J

Japan 21, 571
Jordan 311

K

karyotyping 409
Kerion Celsi 581
ketoconazole 641, 649
killer phenomenon 601
killer toxin 103

L

lectins 261
length polymorphism (PCR-RFLP) 609
leukocyte migration 37 (S2)
lipophilic yeasts 409
liposomal amphotericin B 47, 117, 459, 679
liver 459
liver transplantation 47
L-selection 37 S2)
lung infection 403

M

Malassezia 409, 673
medicinal plants 665
mesenteric lymphadenitis 25 (S2)
miconazole 507
microbial defence 485
microdilution test 231
microsomal function 459
microecology 30 (S1)
Microsporum 559
Microsporum canis 587, 615
molecular epidemiology 7 (S2), 69 (S2)
molecular typing 69 (S2)
monolayer 61 (S2)
mother and children 385
moulds 297, 307, 323, 33 (S2)
mucin 37
mycocin 103
mycotoxins 485, 495

N

nail specimens 645
neonates 3
Neo-Sensitabs® 231
neuraminidase 33
neutropenia 403, 53 (S1), 101 (S2), 121 (S2)

O

obese patients 87 (S2)
ochratoxin A 485, 495
onychomycosis 79, 93, 307, 323, 475, 645, 657, 105 (S2)
opportunists 48 (S1)
oral infection 269
orointestinal tract 68 (S1)
osteomyelitis 577

P

Paracoccidioides brasiliensis 281
paranasal sinuses 33 (S2)
pathogens 48 (S1)
pathogenesis 21, 291, 33 (S2), 49 (S2), 55 (S2)
PCR 71, 239, 515, 7 (S2), 25 (S2)
penicilliosis 347
Penicillium chrysogenum 347
Penicillium mareffei 25 (S2)
peptides 77 (S2)
peripheral blood mononuclear cells 529
periungal wall infection 307
PFGE 409
phaeohyphomycosis 111, 609
pharmacokinetics 3, 17, 79, 87 (S2)
loading dose 591
Phialophora 609
phylogeny 29
pigeon 601
plasma concentration 17, 79, 87 (S2)
Poland 297, 307, 563, 657, 661
polymerase chain reaction 239, 515, 71
predisposing factors 683
premature babies 3, 60 (S1)
premature twins 60 (S1)
prophylaxis 47, 395, 443, 591, 53 (S1), 55 (S2), 121 (S2)
proteinase 48 (S1)
Pseudallescheria boydii 507
psoriasis 63 (S1)
pulmonary infection 675, 679
pulsed-field gel electrophoresis 409
Pycnoporellus fulgens 273

Q

quantification 265

R

RAPD 105 (S2)
rDNA 609

REA 41
renal failure 17, 87 (S2)
renal transplant recipients 75
reductionist paradigm 35 (S1)
regulation 45 (S2)
regulatory T cells 37 (S2)
resistance 453, 577, 39 (S1), 73 (S1)
response regulator proteins 49 (S2)
restriction endonuclease analysis 41
Rhinocladiella 609
Rhizopus oryzae 675
rilopirox 55
RNA isolation 615
rough colony form 521
rRNA 29
rubber particles 465

S

Saccharomyces boulardii 261
saliva 37
Salmonella Typhimurium 261
Saudia Arabia 339
SEM 549
semi-automation 265
septicemia 87 (S2)
serum 37
sialidase 33
sinus infection 225
signaling 49 (S2)
soldiers 475
sporogenesis 549
Sporothrix schenckii 571
sprotrichosis 571
Staib agar 521
standardization 69 (S2)
stress model 30 (S1)
suppository preparation 269
surgical debridement 507
surgical monitoring 225
surveillance cultures 395
surveillance study 555
susceptibility testing 231, 539, 629, 641, 105 (S2)
synergy 115 (S2)
synthetic derivatives 77 (S2)

T

taxonomy 12 (S1)
T2 toxin 485
terbinafine 415, 479, 555, 581, 105 (S2), 111 (S2), 115 (S2)
Thamnophis 107
Thai 25 (S2)
thermal injury 87 (S2)
tinea 335
tinea capitis 319, 331, 421, 559, 587, 73 (S2)
tinea corporis 661
tinea corporis purpurea 587
tinea glabrosa 661
tinea pedis 21, 415, 475, 479, 563
tissue explant assay 255
transmission 385
transmission electron-microscopy 273, 281, 549, 5 (S1)
transepithelial migration 61 (S2)
Trichophyton 559
Trichophyton mentagrophytes 615, 71
Trichophyton mentagrophytes var. *erinacei* 249
Trichophyton rubrum 421, 549, 615, 105 (S2)
Turkey 323
Tween diffusion test 409

U

ultrastructure 273, 281, 549, 5 (S1)
urinary tract infection 285
uroepithelium 255
urticaria 63 (S1)

V

virulence factors 39 (S1), 43 (S1)
voriconazole 539, 83 (S2)

W

weaner pig 485, 495

Y

yeast phase 281, 11 (S2)
yeasts 297, 307, 601, 629

Z

zoo 291
zygomycosis 675

INDEX OF AUTHORS

See also separate Index of Authors for Vol 42 number 3 1999

A

Abe, M. 581
Abu-Elteen, K. H. 311
Abu-Ghdeib, S. I. 665
Ajithados, K. 75, 345
Al-Duboon, A.-H. 331, 335
Alessandrini, C. 111
Ali-Shtayeh, M. S. 665
Al-Rubaiy, K. K. 331, 335
Anğ, Ö. 323
Aubaid, A. H. 249
Ayeni, O. 285
Azevedo, V. 609

B

Bahkali, A. H. 339
Baier, G. 371
Barnes, A. J. 403
Bastert, J. 525, 73(S1)
Bauwens, L. 291
Berndt, A. 485, 495
Bernhardt, H. 529, 68(S1), 29(S2)
Bertsch, T. 19(S2)
Bilenchi, R. 111
Binder, M. 555
Blaschke-Hellmessen, R. 22(S1)
Böhm, K. H. 409
Bradley, M. C. 105(S2)
Brasch, J. 33
Braun, F. 47
Breynaert, J. 645
Bräutigam, M. 415
Bröcker, E.-B. 67
Brocks, K. M. 475
Bruni. A. 549
Buc, J. 465
Büchner, T. 101(S2)

C

Calderone, R. 49(S2)
Calera, J. A. 49(S2)
Caligiorne, R. B. 609
Calvo, T. 649
Carnovale, S. 41
Chang, J. 403
Chen, J. 93
Christensson, B. 239
Chryssanthou, E. 239
Cimerman, S. 567
Colombo, A. L. 567
Costa, M. R. E. 41
Criseo, G. 601
Cuétara, S. 649
Cunha de Oliveira, P. 281
Czaika, V. 577, 73(S2)

D

de Hoog, S. 507
De Meurichy, W. 291
de Moraes Borba, C. 281
de Nazareth Silveira Leal Meirelles, M. 281
de Resende, J. C. P. 641
de Resende, M. A. 609, 641
del Palacio, A. 649
Desmet, P. 231
Devesh, S. 345
Devlioutou-Panagiotidou, D. 319
Dias-Neto, E. 609
Doi, M. 581
Drouhet, E. 11(S2)

E

Ehninger, G. 53(S1)
Elewski, B. E. 105(S2)
El-Sherif, A. M. 515
Enany, M. S. 515
Ernst, J. F. 61(S2)
Erturan, Z. 323
Essink, M. 101(S2)

F

Farina, C. 543
Fegeler, W. 101(S2)
Feio, C. L. 291
Fotidou, D. 319
Franz, R. 453
Frosch, M. 67
Fujisawa, T. 675

G

Głowacka, A. 297, 307, 563, 657, 661
Gabal, M. A. 515
Gachon, C. 465
Gallo, M. 601
Garau, M. 649
Garrett, K. F. 255
Gedek, B. R. 261
Ghannoum, M. A. 105(S2)
Gianotti, R. 587
Ginter, G. 507
Giordani, R. 465
Glasmacher, A. 395, 443, 591
Goglio, A. 543
Göller, M. 19(S2)
Gonçalves, S. E. C. 567
González-Mendoza, A. 347
Gorani. A. 587
Groll, A. H. 431
Grosch-Wörner, I. 385
Guého, E. 673
Guillot, J. 673
Gunzer, U. 371
Gupta, A. K. 225

H

Hacker, J. 29, 371, 39(S1), 69(S2)
Hahn, C. 395, 443, 591
Hamada, T. 37
Hanschke, R. 12(S1)
Harmsen, D. 67, 371, 69(S2)
Hartmann, M. 25(S2)
Hasegawa, A. 71
Haustein, U.-F. 55, 629
Heidemann. H. T. 459
Heinz, W. J. 427
Heise, W. 269
Heller, M. 485, 495
Helm, E. B. 117
Henker, M. 33(S2)
Hermann, C. 619
Hermann, J. 619
Hettler, O. 415
Hiroshima, K. 675
Hiruma, M. 479, 571
Hof, H. 19(S2)
Huerre, M. 11(S2)
Hundal, J. S. 225

I

Iizasa, T. 675
Inselmann, G. 459
Isham, N. 105(S2)

J

Jack, R. S. 35(S1)
Jacob, J. L. 465
Jahns, R. 459
Janaki, C. 75, 345
Janaki, V. R. 345
Jeske, J. 297, 307, 563, 657, 661
Johansen, U. B. 475
Jorgensen, H. O. 475
Just-Nübling, G. 117

K

Kaben, U. 415
Kamalam, A. 75
Kamei, K. 675
Kano, R. 71
Kappe, R. 25(S2), 83(S2)
Katsuoka, K. 581
Kauffman, C. A. 539
Kawada, A. 479, 571
Kern. T. 507
Khatib, R. 285
Khosla, V. K. 225
Kibbler, C. C. 121(S2)
Kielstein, P. 485, 495
Klemm, E. 33(S2)
Klingspor, L. 239
Klinker, H. 371
Knoke, M. 1(S1), 30(S1), 29(S2)
Köhler, G. 39(S1)
Köhler, H. 485, 495
Korting, H. C. 525, 73(S1)
Koussidou-Eremondi, T. 319
Kretschmar, M. 19(S2)
Kroschinsky, F. 53(S1)
Krug, G. 33
Kuijpers, A. F. A. 107
Kume, H. 581
Kunze, R. 529
Kurz, M. 431
Kurzai, O. 427

L

Larssson, L. 239
Lauwers, S. 645
Leeming, J. P. 7(S2)
Leidlich, S. 105(S2)
Leutner, C. 443
Liao, W. 93
Lischewski, A. 371, 385, 69(S2)
López-Martínez, R. 347
Lorf, T. 47
Losem, C. 443
Lupa, S. 297, 307, 563, 657, 661
Lyman, C. A. 255, 77(S2)

M

Manafi, M. 61
Manisco, A. 543
Mann, S. B. S. 225
Mares, D. 549
Marklein, G. 395, 443, 591
Matsumoto, T. 79
Mayser, P. 415
Mendes da Silva, A. M. 281
Michel, S. 29
Migdal, M. 269
Minas, A. 319
Kiraz, M. 323
Miracco, C. 111
Molitor, E. 395, 443, 591
Morgenstern, G. R. 403
Morschhäuser, J. 29, 385, 453, 521, 39(S1)
Moulin-Traffort, J. 273
Mourellou-Tsatsou, O. 319
Mühlschlegel, F. 427
Muhsin, T. M. 331, 335
Müller, A. 47
Müller, F.-M. C. 39(S1), 69(S2), 77(S2)
Müller, G. 485, 495
Müller, J. 1(S1), 3(S1), 5(S1), 1(S2), 3(S2), 5(S2), 6(S2)
Munzel, U. 619
Murphy, J. W. 37(S2)

N

Naem, A. K. 249
Nakamura, Y. 71
Naumann, R. 53(S1)
Navarro, E. 255
Nell, G. 555
Nenoff, P. 55, 629
Neubauer, A. 385
Neumann, L. 347
Nichterlein, T. 19(S2)
Nikawa, H. 37
Nishimura, H. 37
Nishiyama, S. 79, 581
Noguchi, H. 479, 571

O

Ochęcka-Szymańska, A. 297, 307, 563, 657, 661
Oelschlaeger, T. A. 39(S1)
Ohwada, O. 675
Oliveira, S. C. 609
Oppenheim, B. A. 403
Oswald, U. 55, 629

P

Panagoda, G. J. 265
Pandey, A. K. 97
Parvez, S. 339
Penk, A. 3, 17, 87(S2), 91(S2), 97(S2), 111(S2),
Pérez, A. 649, 111(S2)
Pernice, A. 601
Petrini, B. 239
Petutschnig, B. 507
Pfeil, B. 55
Pierer, G. 507
Pittrow, L. 3, 17, 87(S2), 91(S2), 97(S2)
Pizzo, P. A. 255
Plettenberg, A. 269
Polak, A. 355
Pourmojib, M. 615
Prariyachatigul, C. 25(S2)

Q

Qureshi, S. 97

R

Raes-Wuytack, C. 231
Rai, M. K. 97
Rascol, J.-P. 273
Ravenborg, L. R. 475
Regli, P. 273, 465
Reischle, S. 507
Relloso, M. S. 41
Resl, V. 415
Rezaie, S. 615
Riederer, K. M. 285
Rieg, G. K. 117
Rimek, D. 25(S2)
Ringdén, O. 239
Ringe, B. 47
Risan, A. Z. 249
Roberts, D. D. 255
Roggentin, P. 33
Romagnoli, C. 549
Romani, L. 45(S2)
Romano, C. 111, 421, 559
Roos, N. 101(S2)
Rosner, H. 485, 495
Rüchel, R. 47, 619, 48(S1)
Ruhnke, M. 29, 385, 453
Ryder, N. S. 115(S2)

S

Sacchetti, G. 549
Samaranayake, L. P. 37, 265
Sánchez-Alor, G. 649
Sarnow, E. 269
Sastry, K. V. S. S. R. K. 225
Sattler, B. 47
Sauerbruch, T. 395, 443, 951
Scarffe, J. H. 403
Schaller, M. 19(S2)
Schauer, F. 12(S1)
Schauer, R. 33
Schimanski, A. 459
Schlote, F. 269
Schmalreck, A. F. 525
Schmidt, H. 431
Schmidt-Wolf, I. G. H. 395, 443, 591
Schmitt, E. 587
Schneider, M. 431
Schneider, W. 431
Schopf, R. 415
Schrödl, W. 529
Schüppel, K.-F. 107
Schütz, B. 529
Schwabe, D. 431
Schwarze, R. 3
Schwesinger, G. 60(S1)
Schwinn, A. 67, 371
Seebacher, C. 683, 63(S1), 33(S2)

Segal, E. 55(S2)
Senczek, D. 409
Seneczko, F. 297, 307, 563, 657, 661
Sentamilselvi, G. 75, 345
Shah. P. M. 117
Siesenop, U. 409
Silling, G. 101(S2)
Soares de O. Lins, M. 567
Sokolowski, W. 567
Soliman, S. S. 515
Soyer, H. P. 507
Staib, F. 103
Staib, P. 521
Steinmetz, M.-D. 273
Steinmüller, A. 385
Sterry, W. 577, 73(S2)
Stoehr, A. 269
Süß, K. 683
Svejgaard, E. L. 475
Swinne, D. 231, 291

T

Takahashi, H. 71
Taneva, E. 55
Tanuma, H. 21, 581, 79
Thambiah, A. S. 75
Tietz, H.-J. 577, 73(S2)
Tollemar, J. 239
Traenkle, P. 525
Trautmann, M. 385
Tschachler, E. 615
Tsujimoto, H. 71

U

Ulbricht, H. M. 73(S2)
Ullrich, E. 107

V

Vailati, F. 543
Van Looveren, K. 231
Vennewald, I. 683, 33(S2),
Veraldi, S. 587
Vicentini, C. B. 549
Vissiennon, Th. 107

W

Walsh, T. J. 255, 77(S2)
Wanqing, L. 679
Wardelmann, E. 443
Watanabe, S. 71
Watari, T. 71
Weide, M. R. 61(S2)
Weidinger, G. 415
Weihua, P. 679
Wellmer, A. 43(S1)
Wen, H. 93
Wiegand, G. 35(S1)
Wilhelm, M. 371
Willemsen, R. 645
Williamson, E. C. M. 7(S2)
Willinger, B. 61
Wilms, K. 371
Wilson, F. M. 285
Witt, V. 431
Wu, J. 93

Y

Yamashiro, H. 37
Yao, Z. 93
Yeğenoğlu, Y. 323
Yokoi, S. 675
Yoshida, S. 675

Z

Zarins, L. T. 539
Zhirong, Y. 679
Ziebuhr, W. 39(S1)
Zimmermann, K. 29(S2)
Zimmermann, T. 25(S2)